Upgrade to SI Premium - Free Trial

Biogen (BIIB) Increased Pricing on Jan 1- Piper Jaffray

January 2, 2020 7:04 AM
Piper Jaffray analyst Christopher Raymond reiterated a Neutral rating and $305.00 price target on Biogen (NASDAQ: BIIB) after Wolters Kluwer ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments